Yuyue Medical Wu Qun: The acquisition of Kailite is the first move in the new strategic layout of Yuyue's three main tracks

On the evening of May 10, Yuyue Medical issued a major announcement that "Jiangsu Yuyue Medical Equipment Co., Ltd. intends to acquire LenoMed Venture Limited, Kailian Medical Technology (Shanghai) Co., Ltd., Ocean Anchor Investments Limited, Tianjin Tasly Health Industry Investment Partnership (Limited Partnership), Tonghua Dongbao Pharmaceutical Co., Ltd., Suzhou Industrial Park Xinjian Yuan Phase II Venture Capital Enterprise (Limited Partnership) and Ascensia Diabetes Care Holdings AG a total of 50.993% of the equity of Kailite held by 7 parties".

Wu Qun, chairman of Yuyue Medical, said that Yuyue's acquisition of Kailite is the first move in the new strategic layout of Yuyue's three main tracks: Big Breathing, POCT and Infection Control. Kailite has many years of diabetes sensor detection technology, the company has a mature American return technology team, and Yuyue has provided more talent integration resources, has absorbed and continues to absorb more experts at home and abroad to join, to ensure the leading position in product technology, the company will land a new laboratory and R & D center in Nanjing, Shanghai, in the field of diabetes and POCT to create more new products to serve patients.

When it comes to the coordinated development of double hair and the progress of CGM listing, Wu Qun believes that Yuyue has accumulated tens of millions of users at home and abroad in the field of BGM, these users have long used the "Yuyue" brand BGM, which will provide a good user resource base for Yuyue Kailite's CGM, the first generation of Yuyue Kailite's CGM products have obtained CFDA and CE certification, and will be listed at the end of May, while the second generation of products has completed research and development work, ready for clinical work, is expected to be introduced to the market in early 2023. At the same time, Yuyue Kailite's new generation of diabetes management software will also be launched at the same time.

In addition, Wu Qun also said that Yuyue has a long-term and stable cooperative relationship with the endocrinology and diabetes departments of major tertiary hospitals in the domestic market, which will also provide an accurate basis for further iteration and precise innovation of products. At the same time, the company has experience at home and abroad, inside and outside the hospital, diabetes management and service talents, the company has a sound channel foundation and capabilities, efficient organization to ensure the gradual penetration of products. In the future, we will regularly report on the operation of CGM users, so that more patients can better manage and improve diabetes, and will also greatly help doctors and nurses to manage patients more simply and conveniently.